Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does the nadir growth-hormone level predict response to somatostatin-analogue therapy?

Nature Clinical Practice Endocrinology & Metabolism volume 2, pages 12–13 (2006)Cite this article

boxed-textGilbert JA et al. (2005) The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin Endocrinol 62: 742–747

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Freda PU et al. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90: 4465−4473

  2. Petrossians P et al. (2005) Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 152: 61–66

    Article  CAS  Google Scholar 

  3. de Herder WW et al. (2005). Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with sandostatin LAR in acromegaly. Eur J Endocrinol 153: 67–71

    Article  CAS  Google Scholar 

  4. Colao A et al. (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81: 2356–2362

    CAS  PubMed  Google Scholar 

  5. Park C et al. (2004) Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous SRIF activity and response to octreotide. Endocr J 51: 227–236

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Endocrinology, Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Belgium

    Albert Beckers

  2. Research Fellow in Endocrinology, Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Belgium

    Adrian Daly

  3. Staff Clinical Endocrinologist at the Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Belgium

    Patrick Petrossians

Authors
  1. Albert Beckers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adrian Daly
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick Petrossians
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albert Beckers.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beckers, A., Daly, A. & Petrossians, P. Does the nadir growth-hormone level predict response to somatostatin-analogue therapy?. Nat Rev Endocrinol 2, 12–13 (2006). https://doi.org/10.1038/ncpendmet0072

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0072

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing